首页> 外文期刊>Nutrition and Cancer >Dose-Dependent Effects of Selenized Yeast on Total Selenium Levels in Prostatic Tissue of Men With Prostate Cancer
【24h】

Dose-Dependent Effects of Selenized Yeast on Total Selenium Levels in Prostatic Tissue of Men With Prostate Cancer

机译:硒化酵母对前列腺癌男性前列腺组织中总硒水平的剂量依赖性影响

获取原文
获取原文并翻译 | 示例
       

摘要

Although a negative association between serum selenium (or selenium supplementation) and prostate cancer risk has been widely reported (1–8), very little is known about the effects of oral supplementation with selenized yeast on selenium levels in prostate tissue of men with prostate cancer.nIn 2003, Gianduzzo et al. reported results of a prospective trial enrolling 51 men with benign prostatic hyperplasia randomized to receive 200 μg selenized yeast or placebo daily for 1 mo (9). Prostate tissue selenium levels were statistically significantly higher in the supplemented group as compared to placebo (supplement group median = 241 and control group median = 196 ng/gm, P = 0.016) at the end of the study. In another study, Sabichi and colleagues supplemented 66 men with organ-confined prostate cancer with 200 μg selenomethionine (SeMet) or placebo for 14 to 31 days (10). Although baseline serum selenium was similar in the two groups (P = 0.64), post-intervention mean serum selenium level was 15% higher and selenium concentration within the prostate was 22% higher in the SeMet arm as compared to placebo (P = 0.001 and P = 0.021, respectively). The first study was conducted on men with benign prostatic hyperplasia, where it is possible that the tissue environment was different than that found in a prostate with carcinoma. The second study used SeMet, a form of selenium shown to have no effect on prostate cancer incidence in results from the SELECT study (11).nWhile the above studies do give insight into the uptake of various selenium forms by prostate tissue, critical data regarding the uptake of total selenium from selenized yeast in men with prostate cancer are missing. Results from the current study not only address this deficiency in the literature but are also complementary to the Gianduzzo and Sabichi studies, allowing us to compare uptake of various forms of selenium in different prostatic conditions.
机译:尽管血清硒(或硒补充剂)与前列腺癌风险之间存在负相关关系(1-8),但口服硒化酵母对前列腺癌男性前列腺组织硒水平的影响知之甚少在2003年,Gianduzzo等人。报道了一项前瞻性试验的结果,该试验招募了51名良性前列腺增生男性,随机接受每天200μg硒化酵母或安慰剂治疗1个月(9)。研究结束时,补充组的前列腺组织硒水平在统计学上显着高于安慰剂组(补充组中位数= 241,对照组中位数= 196 ng / gm,P = 0.016)。在另一项研究中,Sabichi及其同事用200μg硒代蛋氨酸(SeMet)或安慰剂补充了66名患有器官受限前列腺癌的男性,持续14至31天(10)。尽管两组的基线血清硒水平相似(P = 0.64),但与安慰剂相比,SeMet组的干预后平均血清硒水平高15%,前列腺内硒浓度高22%(P = 0.001和0.001)。 P分别为0.021)。第一次研究是针对前列腺增生的男性进行的,该组织的组织环境可能不同于前列腺癌的组织环境。第二项研究使用的是SeMet,一种硒的形式在SELECT研究中显示对前列腺癌的发病率没有影响(11).n尽管上述研究确实提供了前列腺组织对各种硒形式的摄取的深刻见解,但有关缺少前列腺癌男性中硒化酵母中总硒的摄取。当前研究的结果不仅解决了文献中的这一缺陷,而且还与Gianduzzo和Sabichi研究相辅相成,使我们能够比较不同前列腺状况下各种形式的硒的吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号